Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation.

Viola F, Mapelli C, Villani E, Tresca Carducci F, Vezzola D, Ratiglia R.

Eye (Lond). 2010 Aug;24(8):1344-51. doi: 10.1038/eye.2010.33. Epub 2010 Mar 26.

PMID:
20339389
2.

Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.

Meyerle CB, Freund KB, Iturralde D, Spaide RF, Sorenson JA, Slakter JS, Klancnik JM Jr, Fisher YL, Cooney MJ, Yannuzzi LA.

Retina. 2007 Apr-May;27(4):451-7.

PMID:
17420697
3.

Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.

Saito M, Shiragami C, Shiraga F, Kano M, Iida T.

Am J Ophthalmol. 2010 Mar;149(3):472-81.e1. doi: 10.1016/j.ajo.2009.09.016. Epub 2010 Jan 6.

PMID:
20053392
4.

Single-session photodynamic therapy combined with intravitreal bevacizumab for retinal angiomatous proliferation.

Lo Giudice G, Gismondi M, De Belvis V, Cian R, Tavolato M, Galan A.

Retina. 2009 Jul-Aug;29(7):949-55. doi: 10.1097/IAE.0b013e3181af106d.

PMID:
19584653
5.

Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A.

Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1165-71. doi: 10.1007/s00417-009-1089-3. Epub 2009 Apr 29.

PMID:
19404661
6.

Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.

Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.

Retina. 2007 Apr-May;27(4):432-8.

PMID:
17420694
7.

Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.

Ghazi NG, Knape RM, Kirk TQ, Tiedeman JS, Conway BP.

Retina. 2008 May;28(5):689-95. doi: 10.1097/IAE.0b013e318162d982.

PMID:
18463511
8.

Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.

Parodi MB, Iacono P, Menchini F, Sheth S, Polini G, Pittino R, Bandello F.

Acta Ophthalmol. 2013 May;91(3):267-73. doi: 10.1111/j.1755-3768.2011.02265.x. Epub 2011 Sep 22.

10.

Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.

Gharbiya M, Allievi F, Recupero V, Martini D, Mazzeo L, Gabrieli CB.

Retina. 2009 Jun;29(6):740-9. doi: 10.1097/IAE.0b013e3181a0be1d.

PMID:
19516116
11.

Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.

Moon SW, Kim MS, Kim ES, Yu SY, Kwak HW.

Ophthalmologica. 2011;225(3):169-75. doi: 10.1159/000323811. Epub 2011 Jan 27.

PMID:
21273795
12.

Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.

Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA; Pan-American Collaborative Retina Study Group.

Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.

PMID:
18827735
13.

Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.

Sagong M, Lim S, Chang W.

Am J Ophthalmol. 2012 May;153(5):873-882.e2. doi: 10.1016/j.ajo.2011.09.031. Epub 2012 Jan 20.

PMID:
22265146
14.

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.

Chan WM, Lai TY, Liu DT, Lam DS.

Ophthalmology. 2007 Dec;114(12):2190-6. Epub 2007 Jun 28.

PMID:
17599414
15.

Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.

Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C.

Acta Ophthalmol. 2009 Jun;87(4):404-7. doi: 10.1111/j.1755-3768.2008.01262.x. Epub 2008 Sep 8.

16.
17.

Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.

Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M, Dehghan MH, Moradian S.

BMC Ophthalmol. 2007 Jun 7;7:10.

18.

Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M.

Am J Ophthalmol. 2010 Jul;150(1):48-54.e1. doi: 10.1016/j.ajo.2010.02.008.

PMID:
20609707
19.

One-year outcomes of less frequent bevacizumab in age-related macular degeneration.

Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.

Retina. 2011 Apr;31(4):645-53. doi: 10.1097/IAE.0b013e3182012d18.

PMID:
21358363
20.

[Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].

Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.

J Fr Ophtalmol. 2011 Jun;34(6):376-81. doi: 10.1016/j.jfo.2011.03.004. Epub 2011 May 7. French.

Supplemental Content

Support Center